Understanding Endotoxin and β-Glucan Contamination in Nanotechnology-Based Drug Products

Barry W. Neun,Marina A. Dobrovolskaia
DOI: https://doi.org/10.1007/978-3-030-17148-3_12
2019-01-01
Abstract:Nanotechnology is increasingly used to formulate small molecules, biologics, and nucleic acid-based therapeutics. The attention to this technology is drawn by a variety of benefits including but not limited to the improved circulation time, reduced toxicity and the ability to target tissues and cells of interest. Clinical translation of nanotechnology-based drug products requires, among other investigations, the evaluation for the potential contamination with bacterial endotoxins. In the process of evaluating the safety of nanotechnology-based drug products, screening for additional microbial contaminants, such as beta-glucans, is an emerging new field. Herein, we will provide a general overview of the nanotechnology field and review challenges with estimating endotoxin and beta-glucan contamination in nanoparticle-based drug products.
What problem does this paper attempt to address?